122 related articles for article (PubMed ID: 18630260)
41. [Comparative evaluation of Hebei HIV-1 p24 kit for the detection of human immunodeficiency virus].
Yang YS; Wang RT; Zhang XG; Zhang HZ; Wang HF; Li ZL; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):8-10. PubMed ID: 17429521
[TBL] [Abstract][Full Text] [Related]
42. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics.
Nakahara K; Wakasa-Morimoto C; Kobayashi M; Miki S; Noshi T; Seki T; Kanamori-Koyama M; Kawauchi S; Suyama A; Fujishita T; Yoshinaga T; Garvey EP; Johns BA; Foster SA; Underwood MR; Sato A; Fujiwara T
Antiviral Res; 2009 Feb; 81(2):141-6. PubMed ID: 19027039
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of HIV-1 replication by long-term treatment with a chimeric RNA containing shRNA and TAR decoy RNA.
Barnor JS; Habu Y; Yamamoto N; Miyano-Kurosaki N; Ishikawa K; Yamamoto N; Takaku H
Antiviral Res; 2009 Aug; 83(2):156-64. PubMed ID: 19397929
[TBL] [Abstract][Full Text] [Related]
44. trans-Platinum reporting for duty.
Burdette S
Chem Biol; 2006 May; 13(5):465-7. PubMed ID: 16720266
[TBL] [Abstract][Full Text] [Related]
45. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
46. Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase.
Du L; Zhao YX; Yang LM; Zheng YT; Tang Y; Shen X; Jiang HL
Acta Pharmacol Sin; 2008 Oct; 29(10):1261-7. PubMed ID: 18817633
[TBL] [Abstract][Full Text] [Related]
47. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro.
Pang W; Wang RR; Yang LM; Liu CM; Tien P; Zheng YT
Virology; 2008 Jul; 377(1):80-7. PubMed ID: 18499209
[TBL] [Abstract][Full Text] [Related]
48. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Zhan P; Liu X; Cao Y; Wang Y; Pannecouque C; De Clercq E
Bioorg Med Chem Lett; 2008 Oct; 18(20):5368-71. PubMed ID: 18824350
[TBL] [Abstract][Full Text] [Related]
49. Efficient magnetic bead-based separation of HIV-1-infected cells using an improved reporter virus system reveals that p53 up-regulation occurs exclusively in the virus-expressing cell population.
Imbeault M; Lodge R; Ouellet M; Tremblay MJ
Virology; 2009 Oct; 393(1):160-7. PubMed ID: 19692106
[TBL] [Abstract][Full Text] [Related]
50. A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection.
Liao CH; Kuang YQ; Liu HL; Zheng YT; Su B
AIDS; 2007 Dec; 21 Suppl 8():S19-26. PubMed ID: 18172386
[TBL] [Abstract][Full Text] [Related]
51. [Establishment of a cell-based filovirus entry inhibitor evaluation system].
Chen Q; Guo Y
Yao Xue Xue Bao; 2015 Dec; 50(12):1538-44. PubMed ID: 27169274
[TBL] [Abstract][Full Text] [Related]
52. A luciferase-based screening method for inhibitors of alphavirus replication applied to nucleoside analogues.
Pohjala L; Barai V; Azhayev A; Lapinjoki S; Ahola T
Antiviral Res; 2008 Jun; 78(3):215-22. PubMed ID: 18294708
[TBL] [Abstract][Full Text] [Related]
53. Technology evaluation: GEM-92, Hybridon Inc.
Zheng R
Curr Opin Mol Ther; 1999 Aug; 1(4):521-3. PubMed ID: 11713769
[TBL] [Abstract][Full Text] [Related]
54. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors.
Blair WS; Isaacson J; Li X; Cao J; Peng Q; Kong GF; Patick AK
Antiviral Res; 2005 Feb; 65(2):107-16. PubMed ID: 15708637
[TBL] [Abstract][Full Text] [Related]
55. Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.
Adelson ME; Pacchia AL; Kaul M; Rando RF; Ron Y; Peltz SW; Dougherty JP
Antimicrob Agents Chemother; 2003 Feb; 47(2):501-8. PubMed ID: 12543650
[TBL] [Abstract][Full Text] [Related]
56. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
[TBL] [Abstract][Full Text] [Related]
57. beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL.
Zhang M; Huang Q; Huang Y; Wood O; Yuan W; Chancey C; Daniel S; Rios M; Hewlett I; Clouse KA; Dayton AI
Retrovirology; 2008 Sep; 5():82. PubMed ID: 18808673
[TBL] [Abstract][Full Text] [Related]
58. Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets.
Yu L; Mohanram V; Simonson OE; Smith CI; Spetz AL; Mohamed AJ
Biochem Biophys Res Commun; 2009 Jul; 385(1):100-5. PubMed ID: 19426715
[TBL] [Abstract][Full Text] [Related]
59. Synergistic antivirus effect of combined administration of Combivir with Angelica polysaccharide sulfate.
Yang T; Jia M; Yue Z; Cheng Y; Zhang X; Huang J; Zhou S; Mei Q
Int J Biol Macromol; 2013 Feb; 53():122-6. PubMed ID: 23153762
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and antiviral activities of novel acylhydrazone derivatives targeting HIV-1 capsid protein.
Tian B; He M; Tang S; Hewlett I; Tan Z; Li J; Jin Y; Yang M
Bioorg Med Chem Lett; 2009 Apr; 19(8):2162-7. PubMed ID: 19297155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
